K-ras Oncogene – Talk Bio

BridgeBio Oncology Therapeutics Goes Public via $450M SPAC Merger

2 months ago talkbio0Tagged Biochemical Pathway, BridgeBio, cancer pipeline, Helix (Snails), inhibitors, K-ras Oncogene, KRAS, Merger, Neoplasms, PI3 K pathway, ras Oncogene, SPAC

BridgeBio, oncology, SPAC merger, Helix Acquisition Corp. II, KRAS inhibitors, cancer pipeline, RAS pathway, PI3K pathway

FDA Delays Decision on Amgen’s Lumakras and Vectibix Combination for Metastatic Colorectal Cancer

6 months ago talkbio0Tagged amgen, G12C mutation, K-ras Oncogene, Lumakras, Metastasis from malignant neoplasm of colon and/or rectum, panitumumab, sotorasib, United States Food and Drug Administration, Vectibix

FDA, Amgen, Lumakras, Vectibix, metastatic colorectal cancer, KRAS G12C mutation, sotorasib, panitumumab

FDA Criticizes Bristol Myers Squibb for Misleading Efficacy Claims on Krazati Website

9 months ago talkbio0Tagged Cancer Therapeutic Procedure, Claims, Effectiveness, K-ras Oncogene, KRAZATI, Myers, Non-Small Cell Lung Carcinoma, non-small-cell lung cancer, squibb, United States Food and Drug Administration

Bristol Myers Squibb, FDA, Krazati, misleading efficacy claims, non-small-cell lung cancer, NSCLC, KRAS G12C-mutated, cancer treatment

FDA Approves Adagrasib (Krazati) with Cetuximab for KRAS G12C-Mutated Colorectal Cancer

10 months ago talkbio0Tagged adagrasib, amgen, Approved, cetuximab, Colorectal Carcinoma, G12C, K-ras Oncogene, KRAZATI, Lumakras, Myers, squibb, United States Food and Drug Administration

Adagrasib, Krazati, Cetuximab, KRAS G12C, Colorectal Cancer, FDA Approval, Bristol Myers Squibb, Mirati Therapeutics, Amgen, Lumakras

BMS’s KRAS Inhibitor Krazati Receives FDA Approval for Colorectal Cancer Treatment

10 months ago talkbio0Tagged adagrasib, Approved, cetuximab, Colorectal Carcinoma, Inhibitor, K-ras Oncogene, KRAZATI, Myers, squibb, United States Food and Drug Administration

Krazati, Bristol Myers Squibb, FDA approval, colorectal cancer, KRAS inhibitor, adagrasib, cetuximab

Bristol Myers’ KRAS Confirmatory Data Avoid Amgen’s Flaws but Leave FDA Prospect Unclear

11 months ago talkbio0Tagged Accelerated, amgen, approval pathway, clinical benefits, confirmatory data, confirmatory trials, K-ras Oncogene, Myers, oncology therapies, squibb, United States Food and Drug Administration

Bristol Myers Squibb, KRAS confirmatory data, Amgen, FDA, accelerated approval pathway, oncology therapies, clinical benefits, confirmatory trials

BMS Details Confirmatory Trial Win for KRAS Inhibitor Krazati

11 months ago talkbio0Tagged Accelerated, Approved, Confirmatory Trial, Inhibitor, K-ras Oncogene, KRAZATI, Myers, Non-Small Cell Lung Carcinoma, Pharmacotherapy, Progression-Free Survival, squibb, United States Food and Drug Administration

Bristol Myers Squibb, Krazati, KRAS inhibitor, confirmatory trial, non-small cell lung cancer (NSCLC), progression-free survival (PFS), chemotherapy, accelerated approval, FDA

Biotech Roundup: Compugen, Nxera Milestone Payments; Insmed Seeks $650M Offering

11 months ago talkbio0Tagged AstraZeneca, Bio, BMS, Breyanzi, Burning Mouth Syndrome, Celcuity, Compugen, K-ras Oncogene, luteolin-7-O-diglucuronide 4'-O-glucuronosyltransferase activity, milestone payments, Nordisk, Novartis, Nxera, United States Food and Drug Administration

Compugen, Nxera, milestone payments, Insmed, $650M offering, biotech, pharmaceuticals, Celcuity, Weave Bio, AstraZeneca, Novo Nordisk Foundation, FDA, LDT rule, BMS, Breyanzi, KRAS drug, Novartis